Hepatology
Experts in the development and management of all aspects of MASH/MASLD, and viral hepatitis clinical trials
As a global leader in hepatology and MASH research, ICON delivers clinical expertise, experience, data and best practices to drive your program forward.
Our experts partner with sponsors, investigators, patients, and other collaborators to deliver strategic, data-driven solutions in hepatology and viral hepatitis studies.
-
140
Studies conducted in hepatology & viral hepatitis -
23,385
Patients -
7,100+
Sites worldwide
Our clinical trial experience includes 51 studies in MASH/MASLD over the past 5 years. In total, ICON has supported 16 ph III industry sponsored MASH/MASLD studies, providing enrollment/retention services for 12 of those studies over the past 5 years.
In addition, we have supported clinical research in a range of indications, including:
- Cholestasis
- Cirrhosis
- Fatty liver disease
- Hepatic encephalopathy
- Hepatobiliary disease or hepatic impairment, (non-specified)
- Liver disease (other)
- Liver impairment / failure
- Liver transplant
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis (PSC)
- Veno-occlusive disease
Our team is built of MDs, statisticians, regulatory scientists, DPDs, PMs, CTMs, and CRAs with hepatology-specific expertise who understand these complex patient populations and study protocols.
This experience, combined with our data capabilities and global infrastructure, provides clients with greater access to patients, advanced imaging support and overall advancement of hepatology research.
Patient-centric approach
We are motivated in our daily work by the patients these treatments help, and we work to make clinical trial participation as convenient as possible for patients worldwide. We’ve crafted a superior patient journey, increasing access for potential participants, reducing the burden of participation, and enabling a truly patient-first experience throughout the entire development journey. Our protocols consider a patient’s daily life and standard of care and are free from unnecessary burdens and nuances. Building patient-focused studies not only helps patients who are enrolled but ultimately leads to faster approvals and widespread availability for all hepatology patients.
Webinar: Digital solutions to alleviate MASH clinical trial challenges
Attend our webinar to discover how digital technologies including MRI, MRE and whole slide imaging are helping to address MASH clinical trial challenges.
Webinar: Helping MASH study sites to succeed
How can pharma and biotech companies ensure that their MASH trial sites are set up for success and best supported to drive the development of new therapies? Register for the on-demand webinar.
Hepatology capabilities overview
What is NASH?
Pathophysiology of NASH